On the occasion of the celebration on Monday, November 14, the World Diabetes Day, the Lilly Pharmaceutical Company and the UNLTD Spain social organization have reported that they are supporting two social entrepreneurship projects “to improve the lives of people withdiabetes".
According to the laboratory, this initiative, which focuses on "innovative" actions, also intends to optimize "the life expectancy of diabetes patients."
With the ‘Emprende Inhealth’ program, which “wants to promote social entrepreneurship in the health sector”, both entities “promote the development of different social companies, including Medicsen and Insulclock”.
The aforementioned companies represent “two innovative projects that want to mark a before and after in the life of the 415 million adults that are currently suffering from this disease,” continues Lilly, who adds that the estimate is that “in 2040, thatfigure increases to 642 million ”.
In this sense, this laboratory declares that "Medicsen allows you to customize therapy to each patient at every moment of their daily activity."
"For this, it has an application that incorporates a learning algorithm that connects to third -party sensors to predict variations in the glycemia curve and offer personalized advice for the patient at each moment," he explains.
"Also, Medicsen uses a non -invasive insulin administration device, an intelligent patch connected to the app and totally free of needles," Lilly continues, which adds that Insulclock "is based on a small electronic device that attaches to the majorityof market insulin feathers registering this key information and sending it to an app previously installed on the patient's smartphone. ”